Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (3 shown)

CompletedPhase 1

NCT04973657

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN

Subjects will be administered multiple doses of VK0214 in a cohort dose escalation process. A total of up to 36 subjects will be enrolled in the study, into one…

United States, France24 participantsStarted 2021-06-22

Treatment: VK0214, Placebo

WithdrawnPhase 2

NCT05146284

Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL770 after 12 weeks of treatment in male subjects with…

Location not specified0Started 2023-09

Treatment: PXL770

WithdrawnPhase 2

NCT05200104

Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL065 after 12 weeks of treatment in male subjects with…

Location not specified0Started 2023-09

Treatment: PXL065